Displaying 126–150 of 11035 results for
A lead scientist at La Jolla’s Scripps Research has left the biomedical institute
funny pharma cartoon caption contest
The annual Pharma Innovation Awards are our brand's way of acknowledging the investment pharmaceutical equipment vendors put into developing and improving their products.
One of the industry’s leading small-molecule CDMOs is being acquired for $2.4 billion.
Teva Pharmaceuticals announced this week that its chief financial officer is stepping down.
In an attempt to streamline its supply chain of diabetes drugs in the U.S., Novo Nordisk has scooped up a plant from Purdue Pharma.
On May 24, the FDA approved Zolgensma, a gene therapy product intended to treat children less than two years of age with spinal muscular atrophy but was informed recently by the product’s manufacturer about a data manipulation issue that impacts the accuracy of certain data.
The vaccine candidates will be transferred to the Sabin Vaccine Institute in Washington
Roche’s Tecentriq is showing new promise as an early treatment for bladder cancer.
Eli Lilly has been hit with a subpoena from the New York Attorney General’s Office over the pricing and sales of its insulin treatments.
Takeda Pharma's Korean labor union said Takeda employees faced unfair changes in their jobs and roles during the Takeda Korea and Shire Korea merger.
Fujifilm has acquired a large-scale biologics site near Copenhagen, Denmark.
Oklahoma’s attorney general has made a final attempt to hold Johnson & Johnson’s feet to the fire for its role in the opioid epidemic.
pharma manufacturing news in review
Without the right data management systems in place, data is nothing more than spreadsheets of wasted opportunity for improvement.
As far as M&A deals go, 2019 has started off with a boom.
Mylan has reached a tentative agreement to resolve an investigation that it underpaid the government for EpiPens.
In his latest attempt to lower the costs of prescription drugs, President Trump has proposed a plan to allow imports from Canada.
The organization issued a civil investigative demand to the drugmaker to see if its biosimilar defense strategy violates federal antitrust laws.
The drugmaker will pay Mylan $62 million for improperly stifling competition for its cancer drugs.
One of the buzziest new painkillers in trials for the last few years has been Pfizer and Ely Lilly’s tanezumab, a nerve growth factor drug.
Novartis CEO Vas Narasimhan pledged in a published interview that the Swiss drugmaker will not sell its generics unit amid a revamp that has prompted rumors about offloading Sandoz.
Novartis’ Entresto already has the potential to hit $3 billion in sales for its current heart failure indication, and with another indication in mind, the company hoped sales could hit $5 billion.
Pfizer has agreed to merge its off-patent drugs business with generic drugmaker Mylan.